ARS Pharmaceuticals, Inc.
NASDAQ:SPRYBiotechnology
-$0.35 today
- Market cap
- $370.95M
- Beta
- 0.83
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.99
Volume 1.70M
Average 1.67M
SPRY Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
ARS Pharmaceuticals, Inc.NASDAQ: SPRY
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 87.5% from a year ago
Other current liabilities stood at $592K at the end of Q1 FY2026, down 87.5% from a year earlier and up 0.7% from the prior quarter. Over 3 fiscal years it compounded at -26.1% a year.
Context
- Other current liabilities amounted to 0.2% of total assets at the end of Q1 FY2026, down 1.2 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -87.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 588K USD
- Year-over-year change
- -74.4%
- 4-year CAGR
- -2.8%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 588K | -74.4% |
| FY2024 | 2024-12-31 | 2.29M | +113.1% |
| FY2023 | 2023-12-31 | 1.08M | -26.2% |
| FY2022 | 2022-12-31 | 1.46M | +120.9% |
| FY2021 | 2021-12-31 | 660K | — |
Other Current Liabilities vs competitors
How SPRY compares with its peers on the latest reported figures
- SPRY's Mar 2026 other current liabilities of $592K is the lowest of the 4 companies compared; the peer median is $64.98M.
- Its year-over-year change of -87.5% is the lowest of 4, against a peer median of +122.2%.
- Other current liabilities amounts to 0.2% of total assets for SPRY, versus a peer median of 8.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $100.86M | +211.5% | +54.4% | 25.7% | |
| Mar 2026 | $64.98M | +122.2% | +61.9% | 8.7% | |
| Mar 2026 | $1.38M | -57.9% | -44.0% | 1.0% | |
SPRYARS Pharmaceuticals, Inc. | Mar 2026 | $592K | -87.5% | -26.1% | 0.2% |
| Peer median (excluding SPRY) | $64.98M | +122.2% | +54.4% | 8.7% | |
Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60.06M | 210.52M | 70.97M | 50.82M | 41.32M |
| Short-term Investments | 0 | 63.86M | 157.39M | 263.21M | 203.67M |
| Net Receivables | 1K | 0 | 795K | 9.16M | 26.35M |
| Inventory | 0 | 0 | 0 | 5.21M | 8.37M |
| Other Current Assets | 0 | 1.01M | 0 | 1.23M | 5.19M |
| Total Current Assets | 60.73M | 277.7M | 231.56M | 334.3M | 284.9M |
| Property, Plant & Equipment (Net) | 693K | 774K | 824K | 1.07M | 2.47M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 7.69M | 14.45M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 23K | 2.96M | 801K | 8.11M | 25.84M |
| Total Non-current Assets | 716K | 3.74M | 1.63M | 16.86M | 42.76M |
| Total Assets | 61.45M | 281.44M | 233.19M | 351.15M | 327.65M |
| Account Payables | 1.79M | 1.66M | 759K | 9.87M | 5.73M |
| Short-term Debt | 3.48M | 0 | 237K | 0 | 0 |
| Tax Payables | 0 | 0 | 4K | 0 | 0 |
| Deferred Revenue | 1.46M | 0 | 0 | 557K | 609K |
| Other Current Liabilities | 660K | 1.46M | 1.08M | 2.29M | 588K |
| Total Current Liabilities | 8.19M | 5.44M | 2.39M | 23.44M | 39.15M |
| Long-term Debt | 4.93M | 0 | 0 | 0 | 96.37M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 3M | 0 | 0 | 1.53M | 1.13M |
| Other Non-current Liabilities | 76.12M | 2.85M | 0 | 69.38M | 76.75M |
| Total Non-current Liabilities | 84.53M | 3.11M | 37K | 70.92M | 174.25M |
| Total Liabilities | 92.72M | 8.55M | 2.43M | 94.36M | 213.39M |
| Common Stock | 3K | 9K | 10K | 10K | 10K |
| Retained Earnings | (42.26M) | (76.94M) | (131.3M) | (123.31M) | (294.6M) |
| Accumulated OCI | 0 | 407K | 49K | 220K | 125K |
| Other Stockholders Equity | 0 | 1 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (31.27M) | 272.89M | 230.76M | 256.8M | 114.26M |
| Total Debt | 9.03M | 481K | 274K | 42K | 96.37M |
| Net Debt | (51.03M) | (210.04M) | (70.7M) | (50.78M) | 55.06M |
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.